Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 84,030 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: therapy Clear all

Conditions: Desmoid Tumor
Interventions: toremifene, conventional surgery; Drug · Procedure
Lead sponsor: Advocate Lutheran General Hospital; Other
Eligibility: 16 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2010
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions: Alendronate, Calcium, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Angioedema
Interventions: Icatibant, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Glioblastoma
Interventions: INCMGA00012, INCAGN01876, SRS, Brain surgery; Drug · Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Acute Myeloid (AML)
Interventions: gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine, MEC (Mitoxantrone, Etoposide, Cytarabine), FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin); Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 28 more

Conditions: Hypertension
Interventions: EHMI, Nurse Educator + EHMI; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Preeclampsia
Interventions: Transthoracic Echocardiography; Diagnostic Test
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor
Interventions: vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cocaine Dependence
Interventions: levodopa/carbidopa, Ropinirole 2 mg/d, Placebo, Ropinirole 4 mg/d; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Kidney Disease, Metabolic Acidosis
Interventions: Sodium bicarbonate, Placebo; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: The Bronx, New York • Cleveland, Ohio

Conditions: Chronic Pain, Suicidal Ideation, Suicide, Attempted, Opioid Use
Interventions: Mindfulness-Based Cognitive Therapy (MBCT), Health Education; Behavioral
Lead sponsor: Canandaigua VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Canandaigua, New York

Conditions: Hemophilia
Interventions: rFVIII; Drug
Lead sponsor: Craig Seaman; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: SP01A; Drug
Lead sponsor: Samaritan Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 7
States / cities: Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 4 more

Conditions: Advanced Cancer, Advanced Malignancies
Interventions: Cemiplimab, Hypofractionated radiotherapy, Cyclophosphamide, Docetaxel, Carboplatin, GM-CSF, Paclitaxel, Pemetrexed; Drug · Radiation
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 40
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 31 more

Conditions: Lymphoma
Interventions: rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 2
States / cities: Los Angeles, California • Omaha, Nebraska

Conditions: Anemia, Iron Deficiency
Interventions: Oral iron supplementation; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Parkinson Disease, Mindfulness
Interventions: Mindfulness Based Walking Therapy (MBWT), Freezing of Gait (FOG) Education; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Temporomandibular Joint, Temporomandibular Joint Dysfunction Syndrome, Temporomandibular Joint Disorder
Interventions: Active release techniques; Procedure
Lead sponsor: Logan College of Chiropractic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Cognition, Attention, Eye Movements
Interventions: Electrical Brain Stimulation, Sham Electrical Brain Stimulation; Device
Lead sponsor: Avniel Ghuman; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alzheimer Disease
Interventions: transdisciplinary approach, multidisciplinary approach; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy, The Metabolic Syndrome
Interventions: Pioglitazone, Exercise Training; Drug · Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 28 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Solid Tumors
Interventions: Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel, Irinotecan, Leucovorin, Oxaliplatin, Fluorouracil; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Phoenix, Arizona • Bellflower, California • Long Beach, California + 13 more

Conditions: Alcoholism
Interventions: Ketogenic Diet (KD), Standard American (SA) Meals and Shakes; Other
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Toremifene in Treating Patients With Desmoid Tumors

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Northwestern University and Access Community Health Network Medication Education Study

Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography

Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma

Cognitive Remediation for Cocaine Dependence

Alkali Therapy in Chronic Kidney Disease

Mindfulness for Pain and Suicide

Weight-based Dosing in Hemophilia A

A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Iron Supplement to Improve Iron Status Following Bariatric Surgery

Moving Mindfully for Freezing of Gait

Effects of Masseter Manual Therapy on Temporomandibular Dysfunction

Neurocognitive Basis of Attention and Eye Movement Guidance in the Real World Scenes

Optimizing Care for Patients With Dementia

ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy

Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Ketogenic Diet (KD) in Alcoholism